ReviewSchizophrenia bulletin2026
Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review.
Review in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glioinflammation: disease-associated microglia and astrocytes in psychiatric disorders, neurodegeneration, and senescence.Frontiers in cellular neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEvidence suggests that patients with schizophrenia (SZ) experience an acceleration of the typical aging process. However, it is unclear whether this process reflects premature aging in early life or accelerated aging in later years. Nevertheless, although the timing of accelerated aging in SZ is unclear, there is a consensus that this process is characterized by dysfunctions in immune-oxidative pathway.
methodsIt is a critical need to understand the mechanisms and trajectory of aging underlying SZ so we can target interventions earlier to the right mechanisms. This paper aims to review the recent literature regarding brain energy metabolism in aging with SZ, mainly focusing on the dysfunctions in immuno-oxidative pathway, limitations of studying aging in SZ, and perspective strategies for future studies.
resultsMost studies reviewed in this paper point toward age-related metabolic and cognitive alterations in individuals with SZ. There are complex relationships between normative aging processes and those in SZ. However, the available data neither definitively reveal when this acceleration occurs within the life span nor attribute premature onset of aging-related changes solely to a diagnosis of SZ.
conclusionsImmuno-oxidative pathway dysregulation represents convergent processes underlying the pathophysiology of both SZ and aging, contributing to synaptic dysfunction, neuronal damage, and cognitive impairment. Further research in this domain, using an innovative accelerated longitudinal design and novel, advanced neuroimaging techniques, might open new avenues for understanding common pathophysiological mechanisms and developing therapeutic interventions targeting these interconnected pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.